Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.